The China Rural Hypertension Control Program (CRHCP) reported that 8.85 percent of participants in villages assigned to an intensive, non-physician-led blood pressure program developed dementia over seven years, compared with 10.55 percent in villages assigned to usual care, an adjusted risk ratio of 0.85 (95 percent confidence interval 0.78 to 0.91, p less than 0.001). The results, presented in a Hot Line session at the European Society of Cardiology (ESC) Congress 2026 in Munich on August 30, 2026, come from 33,995 adults aged 40 and older across 326 villages randomized 1 to 1; trained non-physician community health workers, supervised by primary care doctors, started and adjusted blood pressure medication under a stepped-care protocol aiming for readings below 130 over 80 mmHg.
This is a follow-up, not a new trial. CRHCP first reported a dementia reduction of similar size, about 15 percent, after 48 months of active intervention, in a paper published in Nature Medicine in April 2025, when the gap in blood pressure control between the two groups was largest (a net systolic difference of 22.0 mmHg). The new seven-year data add three more years of observation after the structured intervention phase ended, during which the blood pressure gap narrowed considerably: by year seven, the intervention group's systolic pressure had fallen 17.6 mmHg from baseline versus 2.4 mmHg in the usual-care group. Investigators, led by Professor Yingxian Sun and Dr. Shanshan Zhong of China Medical University in Shenyang, also reported a 13 percent lower rate of cognitive impairment without dementia in the intervention group.
The finding is notable because long-term, trial-level evidence linking blood pressure treatment to a hard dementia diagnosis, rather than a cognitive test score, has been scarce. But the seven-year dementia result was presented as a conference Hot Line abstract and has not yet appeared in a peer-reviewed journal, so it has not undergone the scrutiny a published paper receives. The trial also randomized by village rather than by person, and dementia was tracked as a program-wide outcome rather than broken down by Alzheimer's, vascular, or other subtypes, so the data do not show which kind of dementia was most affected or how any individual's risk might change.